SOURCE: Barrier Therapeutics, Inc.

May 16, 2005 08:00 ET

Barrier Therapeutics to Join NASDAQ Biotechnology Index

PRINCETON, NJ -- (MARKET WIRE) -- May 16, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that it will be added to the NASDAQ Biotechnology Index® effective at market open on Monday, May 23, 2005.

"We are honored and delighted to be selected to join the other leading companies in our industry that comprise the NASDAQ Biotechnology Index," said Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer. "We feel our inclusion in this index validates the strength of our organization, our employees, and our growth to date, including the acceleration of our commercial activities and the further advancement of our clinical programs."

Launched in 1993, the NASDAQ Biotechnology Index includes companies classified according to the FTSE™ Global Classification System as either biotechnology or pharmaceutical. The index is ranked on a semi-annual basis in May and November. All securities in the Index are listed on the NASDAQ National Market and must meet minimum requirements, including market value, average daily share volume and seasoning as a public company among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines in the U.S., a common condition also known as "age spots" or "liver spots," and for the broader indication including related hyperpigmented lesions in Canada. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is in registration, and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, fungal infections, including vaginal candidiasis and onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey, and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Web site:

Contact Information

  • Contacts:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Emily Poe